SANTé

Exciting news! Omar H. Khalil H Khalil will be will be representing @Santé as an advisor at this year's @Science2Startup?forum. ? Omar?leads our biotech practice, working closely with scientific founders across a range of therapeutic areas and modalities out of our Boston office. On March 14, Omar will bring his expertise to S2S 2025 in Cambridge, MA, to discuss the next generation of novel science. Since its inception in 2019, this forum has convened academic researchers, entrepreneurs, executives, and venture capitalists to explore transformative innovation in the biotech sector. Click the link below to learn more: #Science2Startup #Biotech #VentureCapital #VC ?https://lnkd.in/ei5r_iM?

Endovascular Engineering is continuing to change the way we think about cardiovascular health. And with $42M in Series B funding, the company will be able to take its life-saving technology to the next level. The financing round announced this week will help advance next-generation clot removal technology for venous thromboembolism (VTE) - a critical step forward in the fight against pulmonary embolism (PE), which is the third leading cause of cardiovascular death. At SANTé, we are proud to continue our support as a founding investor and excited to see this innovation progress closer to FDA approval. #CardiovascularInnovation #PulmonaryEmbolism #MedTech

In just one year post-FDA approval, FARAPULSE, Inc. has shattered expectations,?generating over $1 billion in sales and treating 200,000+ atrial fibrillation patients. Boston Scientific has?called it the most transformational product in the company’s history. ? Farapulse’s success is a testament to the power of innovation in #MedTech, something we’ve believed in at SANTé from day one. Pulsed field ablation is revolutionizing electrophysiology,?and we’re proud to have played an important role in their early development. #Farapulse #PulsedFieldAblation #MedTech #VC ? https://lnkd.in/g3-QCDTu

We're seeing strong optimism for the life sciences industry in 2025?-?but maintaining this momentum will require close attention to key factors this year such as regulatory stability, investor sentiment, economic conditions, and more. In a new article with MedCity News, Omar H. Khalil Khalil predicts what lies ahead for the sector,?highlighting the critical importance of regulatory stability by the FDA. A predictable approval process will be key to sustaining growth and investor confidence within the biotech sector. Additionally, with capital tightening, some biotech companies are increasingly turning to big pharma to fuel their research and development. As the market stabilizes, the future looks bright for metabolic medicine, alongside emerging areas like immunology - which are set to continue their prominence in the industry. Read more of his insights here: https://lnkd.in/gBs5jeJn

While?the?rise?of?precision?medicine?has been transformative in?the?pharmaceutical industry, we’re also seeing a counter-trend:?the?rise?of?“mega blockbusters”, or?therapies that can treat a broader population?of?patients than ever before. ? Our managing director Omar H. Khalil and Abbas Kazimi?of?Nimbus Therapeutics explore this idea in a new article for?Genetic Engineering & Biotechnology News, highlighting how advances in AI and market dynamics have driven a renewed focus on scalable solutions for conditions such as obesity, which could see a $100 billion market by 2030. From multi-indication autoimmune treatments to next-gen oncology drugs,?the?biotech landscape is changing dramatically. This will continue to be an important era in?the?industry, reshaping how companies deliver value for both patients and investors. ? https://lnkd.in/eFb2P6eN

Congratulations to Reprieve Cardiovascular on being named Emerging MedTech Company of the Year at The NEVY Awards, hosted by New England Venture Capital Association! This award recognizes Reprieve's leadership in reshaping heart failure treatment using state-of-the-art technologies that bring intelligence to decongestion management. Their innovation paves the way for improved outcomes to over 25 million patients worldwide. We’re honored to work with Reprieve Cardiovascular on their journey to redefining heart failure care. https://lnkd.in/ej4gUfyD

We're honored to support RapidPulse, Inc. as they receive?FDA approval for an Investigational Device Exemption study of their groundbreaking cyclic aspiration system. This new approach is aimed at improving treatment efficacy for patients with acute ischemic stroke (AIS). ? This is a major step forward in advancing stroke care, and allows U.S. and European patient enrollment to begin in 2025. Recent clinical trials have already demonstrated the promise of this technology, achieving significantly higher first-pass and frontline success rates compared to current benchmarks. ? At SANTé, we?are proud to work with companies such as Rapid?Pulse as they redefine treatment, and are optimistic for improved patient outcomes worldwide. https://lnkd.in/eMfccsR6?

The operating room just got a bit smarter – and it's set to transform the way surgeries are performed. ? Surgical Safety Technologies Inc. Safety Technologies announced a major step forward this week with enhancements to its OR Black Box?, a solution that optimizes operating room safety and efficiency. This new upgrade integrates advanced predictive capabilities that have previously demonstrated significant improvements - such as a 34.8% reduction in room idle time, 4.8% reduction in staff overtime, and 12.5% fewer operating rooms required.? ? SST continues to push the boundaries of what’s possible in perioperative technology, and @Santé?is proud to support their journey. Looking forward to seeing the impact this innovation will have on clinical and operational outcomes around the world. https://lnkd.in/eShRzVrY

Big news from ABK Biomedical Inc.! The company has secured?FDA approval to advance its Investigational Drug Exemption (IDE) study into Stage 2, focusing on its groundbreaking Eye90 microspheres? technology to treat unresectable Hepatocellular Cancer.?This development could potentially set a new standard in personalized, image-guided cancer care. ? At SANTé, we are proud to play a part in ABK’s journey and ongoing success. We look forward?to seeing the team push the?boundaries of innovation in treatment options for patients in need. https://lnkd.in/ecPJ5vNq

As?a?lead investor, Santé Ventures is thrilled to support Clairity, Inc. as it moves into a new chapter with the announcement of Jeffrey R. Luber Luber?as President, CEO, and Director. Jeffrey is an?award-winning industry leader with expertise in oncology, genetic sequencing, and digital health. With his guidance, @Clairity is set to accelerate their market launch and global expansion in delivering personalized risk assessments for breast cancer worldwide. This appointment represents a significant step forward in making the disease prediction more inclusive and accessible for all. We’re proud to be part of @Clairity’s journey in bringing real change to patient care. https://lnkd.in/gGkKjPHK